We are Invicta Medical™
1B
Sleep Apnea Sufferers Worldwide*
80%
Undiagnosed
$150B
Economic Impact of Sleep Apnea in the US*
When untreated, sleep apnea is linked to serious and costly conditions, including drug-resistant hypertension, obesity, congestive heart failure, type-2 diabetes, atrial fibrillation and more.
Untreated sleep apnea costs the U.S. approximately $150 billion annually, due to the healthcare costs associated with these untreated conditions, as well as loss of productivity, workplace accidents and motor vehicle accidents.
Current solutions are not working. Continuous positive airway pressure (CPAP) therapy accounts for 85% of diagnosed sleep apnea patients, yet nearly half don’t comply with the therapy. The devices are cumbersome, loud, uncomfortable and overall intrusive.
Invicta Medical is changing the sleep apnea treatment paradigm from high-cost, complex machines, to smart, comfortable and cost-effective solutions.
Invicta’s intelligent neurostimulation system is designed to address the shortcomings of existing therapies, which are expensive, intrusive and yield low patient compliance rates.
Invicta has raised $29.5M in funding since 2020 and is backed by leading investors.
Invicta’s Board of Directors have extensive operational and financial experience in medical technologies and life sciences, while its Scientific Advisors hail from top universities and medical institutions, including University of Pennsylvania, Vanderbilt University, Stanford University, Flinders University, and Monash University.
World-class investor syndicate supports demonstrated best-in-class obstructive sleep apnea solution...
USA HQ
SANTA CLARA, CA
All Rights Reserved | Invicta Medical, Inc
*
Source:
"The Price of Fatigue", Harvard Medical School Division of Sleep Medicine and McKinsey & Co., Dec. 2010
These statements have not been evaluated by the Food and Drug Administration.